- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Impact of Tumor Heterogeneity in Ovarian Cancer
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients
EP: 12.Single-Agent Vs Combination Regimens
EP: 13.The Potential Impact of Investigational Therapies
EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer
EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer
EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer
EP: 17.Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays
EP: 18.The Effect of Adverse Event Profiles on Treatment Decisions
EP: 19.Evaluating Long-Term Safety Considerations for Targeted Therapies in Ovarian Cancer
Video content above is prompted by the following:
Impact of Tumor Heterogeneity on Testing Reliability
Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, considerations include the following:
- More recent biopsies are preferred for testing when available.
- Blood-based testing (liquid biopsies) can provide genomic information by sampling circulating tumor DNA from the entire tumor burden.
- Cell-free DNA testing is increasingly useful but cannot yet replace tissue-based testing for protein expression markers like HER2 and folate receptor alpha.
Research continues to develop more comprehensive testing through liquid biopsy approaches.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
